Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data.

As an example, the comparison of all-cause costs between treatment groups in UC first-line advanced therapy, especially for patients treated with UST, was based on a limited number of cases and did not reach statistical significance.

also in 111,027 other papers